

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cutia Therapeutics**  
**科笛集团**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2487)**

**VOLUNTARY ANNOUNCEMENT**

**INCLUSION OF THE COMPANY IN THE  
LIST FOR SOUTHBOUND TRADING LINK  
UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE  
SHENZHEN-HONG KONG STOCK CONNECT**

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company has been included in the list for Southbound Trading Link under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, with effect from 5 September 2023, pursuant to the “Announcement on Adjustment of the Stock List under the Shanghai-Hong Kong Stock Connect” issued by the Shanghai Stock Exchange on 5 September 2023 and “Announcement on Adjustment of the Stock List under the Shenzhen-Hong Kong Stock Connect” issued by the Shenzhen Stock Exchange on 5 September 2023.

The Board believes that the inclusion of the Company in the list for Southbound Trading Link under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect demonstrates market recognition of the business performance, investment value and growth prospects of the Group. This inclusion is expected to further expand the shareholder base of the Company, allow access to a broader investor group in Mainland China, increase trading liquidity of the shares of the Company and enhance the reputation of the Group in the capital market.

The Board would like to thank the shareholders and investors of the Company for their continuous support. The Company will continue to leverage its competitive advantages, endeavor to provide comprehensive dermatology treatment and care solutions to patients and create value for its shareholders.

By order of the Board  
**Cutia Therapeutics**  
**Zhang Lele**  
*Chief Executive Officer and Executive Director*

Hong Kong, 5 September 2023

*As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao, Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.*